Clinical Research Trials Archive – Closed Trials

This is our archive of closed clinical trials, which means that they are no longer accepting new participants or have been concluded. Once a research facility has chosen to close the study, it is sorted into the GPS archive by indication. If you are interested in enrolling in a clinical trial, then please browse our list of active clinical studies.

Zip code

Condition


Search Radius:25 Miles
  • 5
  • 10
  • 15
  • 20
  • 25
  • 30
  • 40
  • 50
  • 100
  • 500
  • All

We've found
9,220
archived clinical trials in
HIV / AIDS

Switch Study to Evaluate F/TAF in HIV-1 Positive Participants Who Are Virologically Suppressed on Regimens Containing FTC/TDF
A Phase 3, Randomized, Double-Blind, Switch Study to Evaluate F/TAF in HIV-1 Positive Subjects Who Are Virologically Suppressed on Regimens Containing FTC/TDF
Status: Enrolling
Updated:  12/31/1969
Therafirst Medical Center
mi
from
Fort Lauderdale, FL
Switch Study to Evaluate F/TAF in HIV-1 Positive Participants Who Are Virologically Suppressed on Regimens Containing FTC/TDF
A Phase 3, Randomized, Double-Blind, Switch Study to Evaluate F/TAF in HIV-1 Positive Subjects Who Are Virologically Suppressed on Regimens Containing FTC/TDF
Status: Enrolling
Updated: 12/31/1969
Therafirst Medical Center
mi
from
Fort Lauderdale, FL
Click here to add this to my saved trials
Switch Study to Evaluate F/TAF in HIV-1 Positive Participants Who Are Virologically Suppressed on Regimens Containing FTC/TDF
A Phase 3, Randomized, Double-Blind, Switch Study to Evaluate F/TAF in HIV-1 Positive Subjects Who Are Virologically Suppressed on Regimens Containing FTC/TDF
Status: Enrolling
Updated:  12/31/1969
Tarrant County Infectious Disease Associates
mi
from
Miami, FL
Switch Study to Evaluate F/TAF in HIV-1 Positive Participants Who Are Virologically Suppressed on Regimens Containing FTC/TDF
A Phase 3, Randomized, Double-Blind, Switch Study to Evaluate F/TAF in HIV-1 Positive Subjects Who Are Virologically Suppressed on Regimens Containing FTC/TDF
Status: Enrolling
Updated: 12/31/1969
Tarrant County Infectious Disease Associates
mi
from
Miami, FL
Click here to add this to my saved trials
Switch Study to Evaluate F/TAF in HIV-1 Positive Participants Who Are Virologically Suppressed on Regimens Containing FTC/TDF
A Phase 3, Randomized, Double-Blind, Switch Study to Evaluate F/TAF in HIV-1 Positive Subjects Who Are Virologically Suppressed on Regimens Containing FTC/TDF
Status: Enrolling
Updated:  12/31/1969
AIDS Healthcare Foundation
mi
from
Tampa, FL
Switch Study to Evaluate F/TAF in HIV-1 Positive Participants Who Are Virologically Suppressed on Regimens Containing FTC/TDF
A Phase 3, Randomized, Double-Blind, Switch Study to Evaluate F/TAF in HIV-1 Positive Subjects Who Are Virologically Suppressed on Regimens Containing FTC/TDF
Status: Enrolling
Updated: 12/31/1969
AIDS Healthcare Foundation
mi
from
Tampa, FL
Click here to add this to my saved trials
Switch Study to Evaluate F/TAF in HIV-1 Positive Participants Who Are Virologically Suppressed on Regimens Containing FTC/TDF
A Phase 3, Randomized, Double-Blind, Switch Study to Evaluate F/TAF in HIV-1 Positive Subjects Who Are Virologically Suppressed on Regimens Containing FTC/TDF
Status: Enrolling
Updated:  12/31/1969
St. Louis University
mi
from
Saint Louis, MO
Switch Study to Evaluate F/TAF in HIV-1 Positive Participants Who Are Virologically Suppressed on Regimens Containing FTC/TDF
A Phase 3, Randomized, Double-Blind, Switch Study to Evaluate F/TAF in HIV-1 Positive Subjects Who Are Virologically Suppressed on Regimens Containing FTC/TDF
Status: Enrolling
Updated: 12/31/1969
St. Louis University
mi
from
Saint Louis, MO
Click here to add this to my saved trials
Switch Study to Evaluate F/TAF in HIV-1 Positive Participants Who Are Virologically Suppressed on Regimens Containing FTC/TDF
A Phase 3, Randomized, Double-Blind, Switch Study to Evaluate F/TAF in HIV-1 Positive Subjects Who Are Virologically Suppressed on Regimens Containing FTC/TDF
Status: Enrolling
Updated:  12/31/1969
Southampton Healthcare, Inc.
mi
from
Saint Louis, MO
Switch Study to Evaluate F/TAF in HIV-1 Positive Participants Who Are Virologically Suppressed on Regimens Containing FTC/TDF
A Phase 3, Randomized, Double-Blind, Switch Study to Evaluate F/TAF in HIV-1 Positive Subjects Who Are Virologically Suppressed on Regimens Containing FTC/TDF
Status: Enrolling
Updated: 12/31/1969
Southampton Healthcare, Inc.
mi
from
Saint Louis, MO
Click here to add this to my saved trials
Switch Study to Evaluate F/TAF in HIV-1 Positive Participants Who Are Virologically Suppressed on Regimens Containing FTC/TDF
A Phase 3, Randomized, Double-Blind, Switch Study to Evaluate F/TAF in HIV-1 Positive Subjects Who Are Virologically Suppressed on Regimens Containing FTC/TDF
Status: Enrolling
Updated:  12/31/1969
Prime Healthcare Services - St Michael's LLC d/b/a Saint Michael's Medical Center
mi
from
Newark, NJ
Switch Study to Evaluate F/TAF in HIV-1 Positive Participants Who Are Virologically Suppressed on Regimens Containing FTC/TDF
A Phase 3, Randomized, Double-Blind, Switch Study to Evaluate F/TAF in HIV-1 Positive Subjects Who Are Virologically Suppressed on Regimens Containing FTC/TDF
Status: Enrolling
Updated: 12/31/1969
Prime Healthcare Services - St Michael's LLC d/b/a Saint Michael's Medical Center
mi
from
Newark, NJ
Click here to add this to my saved trials
Switch Study to Evaluate F/TAF in HIV-1 Positive Participants Who Are Virologically Suppressed on Regimens Containing FTC/TDF
A Phase 3, Randomized, Double-Blind, Switch Study to Evaluate F/TAF in HIV-1 Positive Subjects Who Are Virologically Suppressed on Regimens Containing FTC/TDF
Status: Enrolling
Updated:  12/31/1969
AIDS Arms, Inc./Trinity Health & Wellness Center
mi
from
Fort Worth, TX
Switch Study to Evaluate F/TAF in HIV-1 Positive Participants Who Are Virologically Suppressed on Regimens Containing FTC/TDF
A Phase 3, Randomized, Double-Blind, Switch Study to Evaluate F/TAF in HIV-1 Positive Subjects Who Are Virologically Suppressed on Regimens Containing FTC/TDF
Status: Enrolling
Updated: 12/31/1969
AIDS Arms, Inc./Trinity Health & Wellness Center
mi
from
Fort Worth, TX
Click here to add this to my saved trials
Switch Study to Evaluate F/TAF in HIV-1 Positive Participants Who Are Virologically Suppressed on Regimens Containing FTC/TDF
A Phase 3, Randomized, Double-Blind, Switch Study to Evaluate F/TAF in HIV-1 Positive Subjects Who Are Virologically Suppressed on Regimens Containing FTC/TDF
Status: Enrolling
Updated:  12/31/1969
Dupont Circle Physician's Group
mi
from
Washington,
Switch Study to Evaluate F/TAF in HIV-1 Positive Participants Who Are Virologically Suppressed on Regimens Containing FTC/TDF
A Phase 3, Randomized, Double-Blind, Switch Study to Evaluate F/TAF in HIV-1 Positive Subjects Who Are Virologically Suppressed on Regimens Containing FTC/TDF
Status: Enrolling
Updated: 12/31/1969
Dupont Circle Physician's Group
mi
from
Washington,
Click here to add this to my saved trials
Switch Study to Evaluate F/TAF in HIV-1 Positive Participants Who Are Virologically Suppressed on Regimens Containing FTC/TDF
A Phase 3, Randomized, Double-Blind, Switch Study to Evaluate F/TAF in HIV-1 Positive Subjects Who Are Virologically Suppressed on Regimens Containing FTC/TDF
Status: Enrolling
Updated:  12/31/1969
Whitman Walker Health
mi
from
Washington,
Switch Study to Evaluate F/TAF in HIV-1 Positive Participants Who Are Virologically Suppressed on Regimens Containing FTC/TDF
A Phase 3, Randomized, Double-Blind, Switch Study to Evaluate F/TAF in HIV-1 Positive Subjects Who Are Virologically Suppressed on Regimens Containing FTC/TDF
Status: Enrolling
Updated: 12/31/1969
Whitman Walker Health
mi
from
Washington,
Click here to add this to my saved trials
Switch Study to Evaluate F/TAF in HIV-1 Positive Participants Who Are Virologically Suppressed on Regimens Containing FTC/TDF
A Phase 3, Randomized, Double-Blind, Switch Study to Evaluate F/TAF in HIV-1 Positive Subjects Who Are Virologically Suppressed on Regimens Containing FTC/TDF
Status: Enrolling
Updated:  12/31/1969
Capital Medical Associates, PC
mi
from
Washington,
Switch Study to Evaluate F/TAF in HIV-1 Positive Participants Who Are Virologically Suppressed on Regimens Containing FTC/TDF
A Phase 3, Randomized, Double-Blind, Switch Study to Evaluate F/TAF in HIV-1 Positive Subjects Who Are Virologically Suppressed on Regimens Containing FTC/TDF
Status: Enrolling
Updated: 12/31/1969
Capital Medical Associates, PC
mi
from
Washington,
Click here to add this to my saved trials
Switch Study to Evaluate F/TAF in HIV-1 Positive Participants Who Are Virologically Suppressed on Regimens Containing FTC/TDF
A Phase 3, Randomized, Double-Blind, Switch Study to Evaluate F/TAF in HIV-1 Positive Subjects Who Are Virologically Suppressed on Regimens Containing FTC/TDF
Status: Enrolling
Updated:  12/31/1969
Medical Faculty Associates
mi
from
Washington,
Switch Study to Evaluate F/TAF in HIV-1 Positive Participants Who Are Virologically Suppressed on Regimens Containing FTC/TDF
A Phase 3, Randomized, Double-Blind, Switch Study to Evaluate F/TAF in HIV-1 Positive Subjects Who Are Virologically Suppressed on Regimens Containing FTC/TDF
Status: Enrolling
Updated: 12/31/1969
Medical Faculty Associates
mi
from
Washington,
Click here to add this to my saved trials
Switch Study to Evaluate F/TAF in HIV-1 Positive Participants Who Are Virologically Suppressed on Regimens Containing FTC/TDF
A Phase 3, Randomized, Double-Blind, Switch Study to Evaluate F/TAF in HIV-1 Positive Subjects Who Are Virologically Suppressed on Regimens Containing FTC/TDF
Status: Enrolling
Updated:  12/31/1969
Jacobi Medical Center
mi
from
Bronx, NY
Switch Study to Evaluate F/TAF in HIV-1 Positive Participants Who Are Virologically Suppressed on Regimens Containing FTC/TDF
A Phase 3, Randomized, Double-Blind, Switch Study to Evaluate F/TAF in HIV-1 Positive Subjects Who Are Virologically Suppressed on Regimens Containing FTC/TDF
Status: Enrolling
Updated: 12/31/1969
Jacobi Medical Center
mi
from
Bronx, NY
Click here to add this to my saved trials
Switch Study to Evaluate F/TAF in HIV-1 Positive Participants Who Are Virologically Suppressed on Regimens Containing FTC/TDF
A Phase 3, Randomized, Double-Blind, Switch Study to Evaluate F/TAF in HIV-1 Positive Subjects Who Are Virologically Suppressed on Regimens Containing FTC/TDF
Status: Enrolling
Updated:  12/31/1969
Montefiore Medical Center
mi
from
Bronx, NY
Switch Study to Evaluate F/TAF in HIV-1 Positive Participants Who Are Virologically Suppressed on Regimens Containing FTC/TDF
A Phase 3, Randomized, Double-Blind, Switch Study to Evaluate F/TAF in HIV-1 Positive Subjects Who Are Virologically Suppressed on Regimens Containing FTC/TDF
Status: Enrolling
Updated: 12/31/1969
Montefiore Medical Center
mi
from
Bronx, NY
Click here to add this to my saved trials
CASA: Care and Support Access in HIV Disease
CASA: Care and Support Access Study for Implementation of a Palliative Approach With HIV Treatment
Status: Enrolling
Updated:  12/31/1969
University of Maryland Medical System
mi
from
Baltimore, MD
CASA: Care and Support Access in HIV Disease
CASA: Care and Support Access Study for Implementation of a Palliative Approach With HIV Treatment
Status: Enrolling
Updated: 12/31/1969
University of Maryland Medical System
mi
from
Baltimore, MD
Click here to add this to my saved trials
Translation Evaluation of Aging, Inflammation and HIV in Lung Function (TEAL)
Translation Evaluation of Aging, Inflammation and HIV in Lung Function
Status: Enrolling
Updated:  12/31/1969
University of Pittsburgh
mi
from
Pittsburgh, PA
Translation Evaluation of Aging, Inflammation and HIV in Lung Function (TEAL)
Translation Evaluation of Aging, Inflammation and HIV in Lung Function
Status: Enrolling
Updated: 12/31/1969
University of Pittsburgh
mi
from
Pittsburgh, PA
Click here to add this to my saved trials
Phase II Safety and Acceptability of an Investigational Injectable Product, TMC278LA, for Pre-Exposure Prophylaxis
HPTN 076 - Phase II Safety and Acceptability of an Investigational Injectable Product, TMC278 LA, for Pre-Exposure Prophylaxis (PrEP)
Status: Enrolling
Updated:  12/31/1969
New Jersey Medical School Clinical Research Center
mi
from
Newark, NJ
Phase II Safety and Acceptability of an Investigational Injectable Product, TMC278LA, for Pre-Exposure Prophylaxis
HPTN 076 - Phase II Safety and Acceptability of an Investigational Injectable Product, TMC278 LA, for Pre-Exposure Prophylaxis (PrEP)
Status: Enrolling
Updated: 12/31/1969
New Jersey Medical School Clinical Research Center
mi
from
Newark, NJ
Click here to add this to my saved trials
Phase II Safety and Acceptability of an Investigational Injectable Product, TMC278LA, for Pre-Exposure Prophylaxis
HPTN 076 - Phase II Safety and Acceptability of an Investigational Injectable Product, TMC278 LA, for Pre-Exposure Prophylaxis (PrEP)
Status: Enrolling
Updated:  12/31/1969
Bronx Prevention Center
mi
from
Bronx, NY
Phase II Safety and Acceptability of an Investigational Injectable Product, TMC278LA, for Pre-Exposure Prophylaxis
HPTN 076 - Phase II Safety and Acceptability of an Investigational Injectable Product, TMC278 LA, for Pre-Exposure Prophylaxis (PrEP)
Status: Enrolling
Updated: 12/31/1969
Bronx Prevention Center
mi
from
Bronx, NY
Click here to add this to my saved trials
Phase II Safety and Acceptability of an Investigational Injectable Product, TMC278LA, for Pre-Exposure Prophylaxis
HPTN 076 - Phase II Safety and Acceptability of an Investigational Injectable Product, TMC278 LA, for Pre-Exposure Prophylaxis (PrEP)
Status: Enrolling
Updated:  12/31/1969
Emavundleni Clinical Research Site
mi
from
Cape Town,
Phase II Safety and Acceptability of an Investigational Injectable Product, TMC278LA, for Pre-Exposure Prophylaxis
HPTN 076 - Phase II Safety and Acceptability of an Investigational Injectable Product, TMC278 LA, for Pre-Exposure Prophylaxis (PrEP)
Status: Enrolling
Updated: 12/31/1969
Emavundleni Clinical Research Site
mi
from
Cape Town,
Click here to add this to my saved trials
Get Ready And Empowered About Treatment
Addressing HIV Tx Disparities Through Patient Empowerment
Status: Enrolling
Updated:  12/31/1969
Clinical Directors Network
mi
from
New York, NY
Get Ready And Empowered About Treatment
Addressing HIV Tx Disparities Through Patient Empowerment
Status: Enrolling
Updated: 12/31/1969
Clinical Directors Network
mi
from
New York, NY
Click here to add this to my saved trials
Get Ready And Empowered About Treatment
Addressing HIV Tx Disparities Through Patient Empowerment
Status: Enrolling
Updated:  12/31/1969
University of Rochester
mi
from
Rochester, NY
Get Ready And Empowered About Treatment
Addressing HIV Tx Disparities Through Patient Empowerment
Status: Enrolling
Updated: 12/31/1969
University of Rochester
mi
from
Rochester, NY
Click here to add this to my saved trials
PrEPared and Strong: Clinic-Based PrEP for Black MSM
PrEP for Black MSM: Community-Based Ethnography and Clinic-Based Treatment
Status: Enrolling
Updated:  12/31/1969
Harlem Prevention Center
mi
from
New York, NY
PrEPared and Strong: Clinic-Based PrEP for Black MSM
PrEP for Black MSM: Community-Based Ethnography and Clinic-Based Treatment
Status: Enrolling
Updated: 12/31/1969
Harlem Prevention Center
mi
from
New York, NY
Click here to add this to my saved trials
PrEPared and Strong: Clinic-Based PrEP for Black MSM
PrEP for Black MSM: Community-Based Ethnography and Clinic-Based Treatment
Status: Enrolling
Updated:  12/31/1969
Harlem United
mi
from
New York, NY
PrEPared and Strong: Clinic-Based PrEP for Black MSM
PrEP for Black MSM: Community-Based Ethnography and Clinic-Based Treatment
Status: Enrolling
Updated: 12/31/1969
Harlem United
mi
from
New York, NY
Click here to add this to my saved trials
Increasing Social Support to Improve HIV Care Engagement and Adherence in St. Petersburg, Russia
Increasing Social Support to Improve HIV Care Engagement and Adherence
Status: Enrolling
Updated:  12/31/1969
Center for AIDS Intervention Research, Medical College of Wisconsin
mi
from
Milwaukee, WI
Increasing Social Support to Improve HIV Care Engagement and Adherence in St. Petersburg, Russia
Increasing Social Support to Improve HIV Care Engagement and Adherence
Status: Enrolling
Updated: 12/31/1969
Center for AIDS Intervention Research, Medical College of Wisconsin
mi
from
Milwaukee, WI
Click here to add this to my saved trials
Increasing Social Support to Improve HIV Care Engagement and Adherence in St. Petersburg, Russia
Increasing Social Support to Improve HIV Care Engagement and Adherence
Status: Enrolling
Updated:  12/31/1969
Botkin Hospital for Infectious Diseases #30
mi
from
St. Petersburg,
Increasing Social Support to Improve HIV Care Engagement and Adherence in St. Petersburg, Russia
Increasing Social Support to Improve HIV Care Engagement and Adherence
Status: Enrolling
Updated: 12/31/1969
Botkin Hospital for Infectious Diseases #30
mi
from
St. Petersburg,
Click here to add this to my saved trials
Monitoring of 5% Treatment Naïve Intravenous Immunoglobulin (IVIg) Primary Immunodeficiency Disease (PIDD) Patients Using the CareExchange® System: A Pilot Study Using 5% Gammaplex® IVIg in the Home Setting
Monitoring of 5% Treatment Naïve Intravenous Immunoglobulin (IVIg) Primary Immunodeficiency Disease (PIDD) Patients Using the CareExchange® System: A Pilot Study Using 5% Gammaplex® IVIg in the Home Setting
Status: Enrolling
Updated:  12/31/1969
Hoag Medical Group (In Alliance with St. Joseph Heritage Healthcare)
mi
from
Newport Beach, CA
Monitoring of 5% Treatment Naïve Intravenous Immunoglobulin (IVIg) Primary Immunodeficiency Disease (PIDD) Patients Using the CareExchange® System: A Pilot Study Using 5% Gammaplex® IVIg in the Home Setting
Monitoring of 5% Treatment Naïve Intravenous Immunoglobulin (IVIg) Primary Immunodeficiency Disease (PIDD) Patients Using the CareExchange® System: A Pilot Study Using 5% Gammaplex® IVIg in the Home Setting
Status: Enrolling
Updated: 12/31/1969
Hoag Medical Group (In Alliance with St. Joseph Heritage Healthcare)
mi
from
Newport Beach, CA
Click here to add this to my saved trials
Monitoring of 5% Treatment Naïve Intravenous Immunoglobulin (IVIg) Primary Immunodeficiency Disease (PIDD) Patients Using the CareExchange® System: A Pilot Study Using 5% Gammaplex® IVIg in the Home Setting
Monitoring of 5% Treatment Naïve Intravenous Immunoglobulin (IVIg) Primary Immunodeficiency Disease (PIDD) Patients Using the CareExchange® System: A Pilot Study Using 5% Gammaplex® IVIg in the Home Setting
Status: Enrolling
Updated:  12/31/1969
IMMUNEOe International Research Centers
mi
from
Centennial, CO
Monitoring of 5% Treatment Naïve Intravenous Immunoglobulin (IVIg) Primary Immunodeficiency Disease (PIDD) Patients Using the CareExchange® System: A Pilot Study Using 5% Gammaplex® IVIg in the Home Setting
Monitoring of 5% Treatment Naïve Intravenous Immunoglobulin (IVIg) Primary Immunodeficiency Disease (PIDD) Patients Using the CareExchange® System: A Pilot Study Using 5% Gammaplex® IVIg in the Home Setting
Status: Enrolling
Updated: 12/31/1969
IMMUNEOe International Research Centers
mi
from
Centennial, CO
Click here to add this to my saved trials
Monitoring of 5% Treatment Naïve Intravenous Immunoglobulin (IVIg) Primary Immunodeficiency Disease (PIDD) Patients Using the CareExchange® System: A Pilot Study Using 5% Gammaplex® IVIg in the Home Setting
Monitoring of 5% Treatment Naïve Intravenous Immunoglobulin (IVIg) Primary Immunodeficiency Disease (PIDD) Patients Using the CareExchange® System: A Pilot Study Using 5% Gammaplex® IVIg in the Home Setting
Status: Enrolling
Updated:  12/31/1969
Atlanta ENT
mi
from
Atlanta, GA
Monitoring of 5% Treatment Naïve Intravenous Immunoglobulin (IVIg) Primary Immunodeficiency Disease (PIDD) Patients Using the CareExchange® System: A Pilot Study Using 5% Gammaplex® IVIg in the Home Setting
Monitoring of 5% Treatment Naïve Intravenous Immunoglobulin (IVIg) Primary Immunodeficiency Disease (PIDD) Patients Using the CareExchange® System: A Pilot Study Using 5% Gammaplex® IVIg in the Home Setting
Status: Enrolling
Updated: 12/31/1969
Atlanta ENT
mi
from
Atlanta, GA
Click here to add this to my saved trials
Monitoring of 5% Treatment Naïve Intravenous Immunoglobulin (IVIg) Primary Immunodeficiency Disease (PIDD) Patients Using the CareExchange® System: A Pilot Study Using 5% Gammaplex® IVIg in the Home Setting
Monitoring of 5% Treatment Naïve Intravenous Immunoglobulin (IVIg) Primary Immunodeficiency Disease (PIDD) Patients Using the CareExchange® System: A Pilot Study Using 5% Gammaplex® IVIg in the Home Setting
Status: Enrolling
Updated:  12/31/1969
AxelaCare Health Solutions, LLC
mi
from
Lenexa, KA
Monitoring of 5% Treatment Naïve Intravenous Immunoglobulin (IVIg) Primary Immunodeficiency Disease (PIDD) Patients Using the CareExchange® System: A Pilot Study Using 5% Gammaplex® IVIg in the Home Setting
Monitoring of 5% Treatment Naïve Intravenous Immunoglobulin (IVIg) Primary Immunodeficiency Disease (PIDD) Patients Using the CareExchange® System: A Pilot Study Using 5% Gammaplex® IVIg in the Home Setting
Status: Enrolling
Updated: 12/31/1969
AxelaCare Health Solutions, LLC
mi
from
Lenexa, KA
Click here to add this to my saved trials
Evaluating the Safety, Tolerability, and Pharmacokinetics of an Investigational, Injectable HIV Medicine (GSK1265744) in HIV-Uninfected Adults
A Phase IIa Study to Evaluate the Safety, Tolerability and Pharmacokinetics of the Investigational Injectable HIV Integrase Inhibitor, GSK1265744, in HIV-uninfected Men and Women
Status: Enrolling
Updated:  12/31/1969
UCLA CARE Center CRS
mi
from
Los Angeles, CA
Evaluating the Safety, Tolerability, and Pharmacokinetics of an Investigational, Injectable HIV Medicine (GSK1265744) in HIV-Uninfected Adults
A Phase IIa Study to Evaluate the Safety, Tolerability and Pharmacokinetics of the Investigational Injectable HIV Integrase Inhibitor, GSK1265744, in HIV-uninfected Men and Women
Status: Enrolling
Updated: 12/31/1969
UCLA CARE Center CRS
mi
from
Los Angeles, CA
Click here to add this to my saved trials
Evaluating the Safety, Tolerability, and Pharmacokinetics of an Investigational, Injectable HIV Medicine (GSK1265744) in HIV-Uninfected Adults
A Phase IIa Study to Evaluate the Safety, Tolerability and Pharmacokinetics of the Investigational Injectable HIV Integrase Inhibitor, GSK1265744, in HIV-uninfected Men and Women
Status: Enrolling
Updated:  12/31/1969
Bridge HIV CRS
mi
from
San Francisco, CA
Evaluating the Safety, Tolerability, and Pharmacokinetics of an Investigational, Injectable HIV Medicine (GSK1265744) in HIV-Uninfected Adults
A Phase IIa Study to Evaluate the Safety, Tolerability and Pharmacokinetics of the Investigational Injectable HIV Integrase Inhibitor, GSK1265744, in HIV-uninfected Men and Women
Status: Enrolling
Updated: 12/31/1969
Bridge HIV CRS
mi
from
San Francisco, CA
Click here to add this to my saved trials
Evaluating the Safety, Tolerability, and Pharmacokinetics of an Investigational, Injectable HIV Medicine (GSK1265744) in HIV-Uninfected Adults
A Phase IIa Study to Evaluate the Safety, Tolerability and Pharmacokinetics of the Investigational Injectable HIV Integrase Inhibitor, GSK1265744, in HIV-uninfected Men and Women
Status: Enrolling
Updated:  12/31/1969
Chapel Hill CRS
mi
from
Chapel Hill, NC
Evaluating the Safety, Tolerability, and Pharmacokinetics of an Investigational, Injectable HIV Medicine (GSK1265744) in HIV-Uninfected Adults
A Phase IIa Study to Evaluate the Safety, Tolerability and Pharmacokinetics of the Investigational Injectable HIV Integrase Inhibitor, GSK1265744, in HIV-uninfected Men and Women
Status: Enrolling
Updated: 12/31/1969
Chapel Hill CRS
mi
from
Chapel Hill, NC
Click here to add this to my saved trials
Evaluating the Safety, Tolerability, and Pharmacokinetics of an Investigational, Injectable HIV Medicine (GSK1265744) in HIV-Uninfected Adults
A Phase IIa Study to Evaluate the Safety, Tolerability and Pharmacokinetics of the Investigational Injectable HIV Integrase Inhibitor, GSK1265744, in HIV-uninfected Men and Women
Status: Enrolling
Updated:  12/31/1969
Instituto de Pesquisa Clinica Evandro Chagas (IPEC) CRS
mi
from
Rio de Janeiro,
Evaluating the Safety, Tolerability, and Pharmacokinetics of an Investigational, Injectable HIV Medicine (GSK1265744) in HIV-Uninfected Adults
A Phase IIa Study to Evaluate the Safety, Tolerability and Pharmacokinetics of the Investigational Injectable HIV Integrase Inhibitor, GSK1265744, in HIV-uninfected Men and Women
Status: Enrolling
Updated: 12/31/1969
Instituto de Pesquisa Clinica Evandro Chagas (IPEC) CRS
mi
from
Rio de Janeiro,
Click here to add this to my saved trials
Evaluating the Safety, Tolerability, and Pharmacokinetics of an Investigational, Injectable HIV Medicine (GSK1265744) in HIV-Uninfected Adults
A Phase IIa Study to Evaluate the Safety, Tolerability and Pharmacokinetics of the Investigational Injectable HIV Integrase Inhibitor, GSK1265744, in HIV-uninfected Men and Women
Status: Enrolling
Updated:  12/31/1969
George Washington University CRS
mi
from
Washington,
Evaluating the Safety, Tolerability, and Pharmacokinetics of an Investigational, Injectable HIV Medicine (GSK1265744) in HIV-Uninfected Adults
A Phase IIa Study to Evaluate the Safety, Tolerability and Pharmacokinetics of the Investigational Injectable HIV Integrase Inhibitor, GSK1265744, in HIV-uninfected Men and Women
Status: Enrolling
Updated: 12/31/1969
George Washington University CRS
mi
from
Washington,
Click here to add this to my saved trials
Females of African American Legacy Empowering Self (FemAALES)
Reducing HIV/STD Risk in African American Women With At-Risk Male Partners
Status: Enrolling
Updated:  12/31/1969
St. John's Well Child and Family Center
mi
from
Los Angeles, CA
Females of African American Legacy Empowering Self (FemAALES)
Reducing HIV/STD Risk in African American Women With At-Risk Male Partners
Status: Enrolling
Updated: 12/31/1969
St. John's Well Child and Family Center
mi
from
Los Angeles, CA
Click here to add this to my saved trials
Females of African American Legacy Empowering Self (FemAALES)
Reducing HIV/STD Risk in African American Women With At-Risk Male Partners
Status: Enrolling
Updated:  12/31/1969
Charles Drew University of Medicine and Science
mi
from
Los Angeles, CA
Females of African American Legacy Empowering Self (FemAALES)
Reducing HIV/STD Risk in African American Women With At-Risk Male Partners
Status: Enrolling
Updated: 12/31/1969
Charles Drew University of Medicine and Science
mi
from
Los Angeles, CA
Click here to add this to my saved trials
Evaluating the Safety and Effectiveness of Interferon-Free Treatment of Hepatitis C Virus Infection in HIV-Coinfected Adults on Antiretroviral Therapy
Interferon-Free Therapy for Chronic Hepatitis C Virus Genotype 1 Infection in Participants With HIV-1 Coinfection Receiving Concurrent Antiretroviral Therapy (C_ASCENT)
Status: Enrolling
Updated:  12/31/1969
Alabama CRS
mi
from
Birmingham, AL
Evaluating the Safety and Effectiveness of Interferon-Free Treatment of Hepatitis C Virus Infection in HIV-Coinfected Adults on Antiretroviral Therapy
Interferon-Free Therapy for Chronic Hepatitis C Virus Genotype 1 Infection in Participants With HIV-1 Coinfection Receiving Concurrent Antiretroviral Therapy (C_ASCENT)
Status: Enrolling
Updated: 12/31/1969
Alabama CRS
mi
from
Birmingham, AL
Click here to add this to my saved trials
Evaluating the Safety and Effectiveness of Interferon-Free Treatment of Hepatitis C Virus Infection in HIV-Coinfected Adults on Antiretroviral Therapy
Interferon-Free Therapy for Chronic Hepatitis C Virus Genotype 1 Infection in Participants With HIV-1 Coinfection Receiving Concurrent Antiretroviral Therapy (C_ASCENT)
Status: Enrolling
Updated:  12/31/1969
UCLA CARE Center CRS
mi
from
Los Angeles, CA
Evaluating the Safety and Effectiveness of Interferon-Free Treatment of Hepatitis C Virus Infection in HIV-Coinfected Adults on Antiretroviral Therapy
Interferon-Free Therapy for Chronic Hepatitis C Virus Genotype 1 Infection in Participants With HIV-1 Coinfection Receiving Concurrent Antiretroviral Therapy (C_ASCENT)
Status: Enrolling
Updated: 12/31/1969
UCLA CARE Center CRS
mi
from
Los Angeles, CA
Click here to add this to my saved trials
Evaluating the Safety and Effectiveness of Interferon-Free Treatment of Hepatitis C Virus Infection in HIV-Coinfected Adults on Antiretroviral Therapy
Interferon-Free Therapy for Chronic Hepatitis C Virus Genotype 1 Infection in Participants With HIV-1 Coinfection Receiving Concurrent Antiretroviral Therapy (C_ASCENT)
Status: Enrolling
Updated:  12/31/1969
University of Colorado Hospital CRS
mi
from
Aurora, CO
Evaluating the Safety and Effectiveness of Interferon-Free Treatment of Hepatitis C Virus Infection in HIV-Coinfected Adults on Antiretroviral Therapy
Interferon-Free Therapy for Chronic Hepatitis C Virus Genotype 1 Infection in Participants With HIV-1 Coinfection Receiving Concurrent Antiretroviral Therapy (C_ASCENT)
Status: Enrolling
Updated: 12/31/1969
University of Colorado Hospital CRS
mi
from
Aurora, CO
Click here to add this to my saved trials
Evaluating the Safety and Effectiveness of Interferon-Free Treatment of Hepatitis C Virus Infection in HIV-Coinfected Adults on Antiretroviral Therapy
Interferon-Free Therapy for Chronic Hepatitis C Virus Genotype 1 Infection in Participants With HIV-1 Coinfection Receiving Concurrent Antiretroviral Therapy (C_ASCENT)
Status: Enrolling
Updated:  12/31/1969
Rush University CRS
mi
from
Chicago, IL
Evaluating the Safety and Effectiveness of Interferon-Free Treatment of Hepatitis C Virus Infection in HIV-Coinfected Adults on Antiretroviral Therapy
Interferon-Free Therapy for Chronic Hepatitis C Virus Genotype 1 Infection in Participants With HIV-1 Coinfection Receiving Concurrent Antiretroviral Therapy (C_ASCENT)
Status: Enrolling
Updated: 12/31/1969
Rush University CRS
mi
from
Chicago, IL
Click here to add this to my saved trials
Evaluating the Safety and Effectiveness of Interferon-Free Treatment of Hepatitis C Virus Infection in HIV-Coinfected Adults on Antiretroviral Therapy
Interferon-Free Therapy for Chronic Hepatitis C Virus Genotype 1 Infection in Participants With HIV-1 Coinfection Receiving Concurrent Antiretroviral Therapy (C_ASCENT)
Status: Enrolling
Updated:  12/31/1969
Johns Hopkins University CRS
mi
from
Baltimore, MD
Evaluating the Safety and Effectiveness of Interferon-Free Treatment of Hepatitis C Virus Infection in HIV-Coinfected Adults on Antiretroviral Therapy
Interferon-Free Therapy for Chronic Hepatitis C Virus Genotype 1 Infection in Participants With HIV-1 Coinfection Receiving Concurrent Antiretroviral Therapy (C_ASCENT)
Status: Enrolling
Updated: 12/31/1969
Johns Hopkins University CRS
mi
from
Baltimore, MD
Click here to add this to my saved trials
Evaluating the Safety and Effectiveness of Interferon-Free Treatment of Hepatitis C Virus Infection in HIV-Coinfected Adults on Antiretroviral Therapy
Interferon-Free Therapy for Chronic Hepatitis C Virus Genotype 1 Infection in Participants With HIV-1 Coinfection Receiving Concurrent Antiretroviral Therapy (C_ASCENT)
Status: Enrolling
Updated:  12/31/1969
New Jersey Medical School Clinical Research Center CRS
mi
from
Newark, NJ
Evaluating the Safety and Effectiveness of Interferon-Free Treatment of Hepatitis C Virus Infection in HIV-Coinfected Adults on Antiretroviral Therapy
Interferon-Free Therapy for Chronic Hepatitis C Virus Genotype 1 Infection in Participants With HIV-1 Coinfection Receiving Concurrent Antiretroviral Therapy (C_ASCENT)
Status: Enrolling
Updated: 12/31/1969
New Jersey Medical School Clinical Research Center CRS
mi
from
Newark, NJ
Click here to add this to my saved trials
Evaluating the Safety and Effectiveness of Interferon-Free Treatment of Hepatitis C Virus Infection in HIV-Coinfected Adults on Antiretroviral Therapy
Interferon-Free Therapy for Chronic Hepatitis C Virus Genotype 1 Infection in Participants With HIV-1 Coinfection Receiving Concurrent Antiretroviral Therapy (C_ASCENT)
Status: Enrolling
Updated:  12/31/1969
Weill Cornell Chelsea CRS
mi
from
New York, NY
Evaluating the Safety and Effectiveness of Interferon-Free Treatment of Hepatitis C Virus Infection in HIV-Coinfected Adults on Antiretroviral Therapy
Interferon-Free Therapy for Chronic Hepatitis C Virus Genotype 1 Infection in Participants With HIV-1 Coinfection Receiving Concurrent Antiretroviral Therapy (C_ASCENT)
Status: Enrolling
Updated: 12/31/1969
Weill Cornell Chelsea CRS
mi
from
New York, NY
Click here to add this to my saved trials
Evaluating the Safety and Effectiveness of Interferon-Free Treatment of Hepatitis C Virus Infection in HIV-Coinfected Adults on Antiretroviral Therapy
Interferon-Free Therapy for Chronic Hepatitis C Virus Genotype 1 Infection in Participants With HIV-1 Coinfection Receiving Concurrent Antiretroviral Therapy (C_ASCENT)
Status: Enrolling
Updated:  12/31/1969
Cincinnati Clinical Research Site
mi
from
Cincinnati, OH
Evaluating the Safety and Effectiveness of Interferon-Free Treatment of Hepatitis C Virus Infection in HIV-Coinfected Adults on Antiretroviral Therapy
Interferon-Free Therapy for Chronic Hepatitis C Virus Genotype 1 Infection in Participants With HIV-1 Coinfection Receiving Concurrent Antiretroviral Therapy (C_ASCENT)
Status: Enrolling
Updated: 12/31/1969
Cincinnati Clinical Research Site
mi
from
Cincinnati, OH
Click here to add this to my saved trials
Evaluating the Safety and Effectiveness of Interferon-Free Treatment of Hepatitis C Virus Infection in HIV-Coinfected Adults on Antiretroviral Therapy
Interferon-Free Therapy for Chronic Hepatitis C Virus Genotype 1 Infection in Participants With HIV-1 Coinfection Receiving Concurrent Antiretroviral Therapy (C_ASCENT)
Status: Enrolling
Updated:  12/31/1969
Penn Therapeutics Crs
mi
from
Philadelphia, PA
Evaluating the Safety and Effectiveness of Interferon-Free Treatment of Hepatitis C Virus Infection in HIV-Coinfected Adults on Antiretroviral Therapy
Interferon-Free Therapy for Chronic Hepatitis C Virus Genotype 1 Infection in Participants With HIV-1 Coinfection Receiving Concurrent Antiretroviral Therapy (C_ASCENT)
Status: Enrolling
Updated: 12/31/1969
Penn Therapeutics Crs
mi
from
Philadelphia, PA
Click here to add this to my saved trials
Evaluating the Safety and Effectiveness of Interferon-Free Treatment of Hepatitis C Virus Infection in HIV-Coinfected Adults on Antiretroviral Therapy
Interferon-Free Therapy for Chronic Hepatitis C Virus Genotype 1 Infection in Participants With HIV-1 Coinfection Receiving Concurrent Antiretroviral Therapy (C_ASCENT)
Status: Enrolling
Updated:  12/31/1969
University of Pittsburgh CRS
mi
from
Pittsburgh, PA
Evaluating the Safety and Effectiveness of Interferon-Free Treatment of Hepatitis C Virus Infection in HIV-Coinfected Adults on Antiretroviral Therapy
Interferon-Free Therapy for Chronic Hepatitis C Virus Genotype 1 Infection in Participants With HIV-1 Coinfection Receiving Concurrent Antiretroviral Therapy (C_ASCENT)
Status: Enrolling
Updated: 12/31/1969
University of Pittsburgh CRS
mi
from
Pittsburgh, PA
Click here to add this to my saved trials
Evaluating the Safety and Effectiveness of Interferon-Free Treatment of Hepatitis C Virus Infection in HIV-Coinfected Adults on Antiretroviral Therapy
Interferon-Free Therapy for Chronic Hepatitis C Virus Genotype 1 Infection in Participants With HIV-1 Coinfection Receiving Concurrent Antiretroviral Therapy (C_ASCENT)
Status: Enrolling
Updated:  12/31/1969
The Miriam Hospital Clinical Research Site (TMH CRS) CRS
mi
from
Providence, RI
Evaluating the Safety and Effectiveness of Interferon-Free Treatment of Hepatitis C Virus Infection in HIV-Coinfected Adults on Antiretroviral Therapy
Interferon-Free Therapy for Chronic Hepatitis C Virus Genotype 1 Infection in Participants With HIV-1 Coinfection Receiving Concurrent Antiretroviral Therapy (C_ASCENT)
Status: Enrolling
Updated: 12/31/1969
The Miriam Hospital Clinical Research Site (TMH CRS) CRS
mi
from
Providence, RI
Click here to add this to my saved trials
Evaluating the Safety and Effectiveness of Interferon-Free Treatment of Hepatitis C Virus Infection in HIV-Coinfected Adults on Antiretroviral Therapy
Interferon-Free Therapy for Chronic Hepatitis C Virus Genotype 1 Infection in Participants With HIV-1 Coinfection Receiving Concurrent Antiretroviral Therapy (C_ASCENT)
Status: Enrolling
Updated:  12/31/1969
Trinity Health and Wellness Center CRS
mi
from
Dallas, TX
Evaluating the Safety and Effectiveness of Interferon-Free Treatment of Hepatitis C Virus Infection in HIV-Coinfected Adults on Antiretroviral Therapy
Interferon-Free Therapy for Chronic Hepatitis C Virus Genotype 1 Infection in Participants With HIV-1 Coinfection Receiving Concurrent Antiretroviral Therapy (C_ASCENT)
Status: Enrolling
Updated: 12/31/1969
Trinity Health and Wellness Center CRS
mi
from
Dallas, TX
Click here to add this to my saved trials
Evaluating the Safety and Effectiveness of Interferon-Free Treatment of Hepatitis C Virus Infection in HIV-Coinfected Adults on Antiretroviral Therapy
Interferon-Free Therapy for Chronic Hepatitis C Virus Genotype 1 Infection in Participants With HIV-1 Coinfection Receiving Concurrent Antiretroviral Therapy (C_ASCENT)
Status: Enrolling
Updated:  12/31/1969
Houston AIDS Research Team CRS
mi
from
Houston, TX
Evaluating the Safety and Effectiveness of Interferon-Free Treatment of Hepatitis C Virus Infection in HIV-Coinfected Adults on Antiretroviral Therapy
Interferon-Free Therapy for Chronic Hepatitis C Virus Genotype 1 Infection in Participants With HIV-1 Coinfection Receiving Concurrent Antiretroviral Therapy (C_ASCENT)
Status: Enrolling
Updated: 12/31/1969
Houston AIDS Research Team CRS
mi
from
Houston, TX
Click here to add this to my saved trials
Evaluating the Safety and Effectiveness of Interferon-Free Treatment of Hepatitis C Virus Infection in HIV-Coinfected Adults on Antiretroviral Therapy
Interferon-Free Therapy for Chronic Hepatitis C Virus Genotype 1 Infection in Participants With HIV-1 Coinfection Receiving Concurrent Antiretroviral Therapy (C_ASCENT)
Status: Enrolling
Updated:  12/31/1969
University of Washington AIDS CRS
mi
from
Seattle, WA
Evaluating the Safety and Effectiveness of Interferon-Free Treatment of Hepatitis C Virus Infection in HIV-Coinfected Adults on Antiretroviral Therapy
Interferon-Free Therapy for Chronic Hepatitis C Virus Genotype 1 Infection in Participants With HIV-1 Coinfection Receiving Concurrent Antiretroviral Therapy (C_ASCENT)
Status: Enrolling
Updated: 12/31/1969
University of Washington AIDS CRS
mi
from
Seattle, WA
Click here to add this to my saved trials
Evaluating the Safety and Effectiveness of Interferon-Free Treatment of Hepatitis C Virus Infection in HIV-Coinfected Adults on Antiretroviral Therapy
Interferon-Free Therapy for Chronic Hepatitis C Virus Genotype 1 Infection in Participants With HIV-1 Coinfection Receiving Concurrent Antiretroviral Therapy (C_ASCENT)
Status: Enrolling
Updated:  12/31/1969
Puerto Rico AIDS Clinical Trials Unit CRS
mi
from
San Juan,
Evaluating the Safety and Effectiveness of Interferon-Free Treatment of Hepatitis C Virus Infection in HIV-Coinfected Adults on Antiretroviral Therapy
Interferon-Free Therapy for Chronic Hepatitis C Virus Genotype 1 Infection in Participants With HIV-1 Coinfection Receiving Concurrent Antiretroviral Therapy (C_ASCENT)
Status: Enrolling
Updated: 12/31/1969
Puerto Rico AIDS Clinical Trials Unit CRS
mi
from
San Juan,
Click here to add this to my saved trials